Triumph Capital Management’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.12K Hold
13
– – ﹤0.01% 1687
2026
Q2
$1.18K Buy
13
+5
+63% +$419 ﹤0.01% 1645
2026
Q1
$641 Buy
8
+2
+33% +$165 ﹤0.01% 1678
2025
Q4
$512 Buy
+6
New +$492 ﹤0.01% 1640

Other funds holding EW

Triumph Capital Management's EW Position: Q3 2026 in Review

Triumph Capital Management held its Edwards Lifesciences (EW) position steady in Q3 2026 at 13 shares worth $1.12K. The position accounts for ﹤0.01% of the portfolio, ranked #1687.

Triumph Capital Management first reported a position in EW in Q4 2025 and has held it in 4 quarters since. The position peaked at $1.18K in Q2 2026. 1,206 funds tracked by Wall St. Rank hold EW as of Q3 2026.

  • Triumph Capital Management held 13 shares of Edwards Lifesciences worth $1.12K as of Q3 2026.
  • Triumph Capital Management left its Edwards Lifesciences share count unchanged in Q3 2026.
  • Edwards Lifesciences made up ﹤0.01% of Triumph Capital Management's portfolio in Q3 2026, its #1687 holding.
  • Triumph Capital Management first reported a position in Edwards Lifesciences in Q4 2025 and has held it in 4 quarters since.
  • Triumph Capital Management's Edwards Lifesciences position peaked at $1.18K in Q2 2026.
  • 1,206 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2026.

Based on Triumph Capital Management's 13F filing for Q3 2026, filed 14 Oct 2026.